Confira a cotação BIIB hoje e acompanhe as ações Biogen em tempo real. As seções dessa página permitem ver o preço da ação agora, comparar com dados históricos, ver gráficos, dividendos e indicadores ...

Biogen has said it hopes new “real world” data will ensure patients are not put off taking its key multiple sclerosis drug, Tecfidera because of stomach problems that can occur early in treatment.

Biogen generated nearly $6 billion in MS revenue in 2023, although we see these sales declining nearly 10% annually as the firm faces branded competition, generic pressure on Tecfidera ...

Much of that decline was driven by generic competition to Tecfidera around the world, as well as Tysabri’s limited exposure to biosimilars in Europe, Michael McDonnel, Biogen’s outgoing ...

Vumerity (diroximel fumarate) can cause side effects that range from mild to serious. Common side effects include flushing and diarrhea. If side effects become bothersome, talk with your doctor ...

Tecfidera was for years Biogen’s flagship product, accounting for about one-third of the company’s revenue as recently as 2020. The expiry of key patents and entry of lower-cost generic rivals in the ...

The ruling means that Biogen should now have protection from generic competition to Tecfidera in the US until 2028, protecting a product that accounted for $4.4 billion out of total sales of $14.4 ...